Previous 10 | Next 10 |
BEIJING, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products ...
BEIJING, China, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening pro...
BEIJING, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH), a leading precision oncology company in China that specializes in offering molecular profiling tests, early cancer screening products and comp...
Gainers: Iterum Therapeutics (ITRM) +146%.CTI BioPharma (CTIC) +110%.CynergisTek (CTEK) +69%.Nano Dimension (NNDM) +38%.Wanda Sports Group (WSG) +28%.Genetron (GTH) +24%.Allena Pharmaceuticals (ALNA) +20%.Sky Solar (SKYS) +19%.RAPT Therapeutics (RAPT) +19%.Limbach Holdings (LMB) +16%.Los...
Gainers: CTI BioPharma (CTIC) +99%, Genetron Holdings (GTH) +26%, Allena Pharmaceuticals (ALNA) +23%, Neurotrope (NTRP) +20%, Kaleido Biosciences (KLDO) +11%.Losers: Aptorum Group (APM) -41%, Adial Pharmaceuticals (ADIL) -21%, Avalon...
Genetron Holdings' (GTH) blood-based next-generation sequencing ((NGS)) test, HCCscreen, has been granted Breakthrough Device designation by the FDA.HCCscreen is intended for early detection of hepatocellular carcinoma in individuals who are designated to be at high-risk due to chronic H...
BEIJING and GAITHERSBURG, Md., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early can...
China has a considerably large gene pool, a decisive success factor in conducting prospective research in early-stage cancer studies. Local bureaucracy has the power to lead nationwide research. As the early cancer-screening technology matures, the commercial strategy at the current s...
Genetron (GTH) and its partner CStone Pharmaceuticals (CSPHF) have launched a clinical trial in China for the development of a companion diagnostic test for avapritinib, a kinase inhibitor discovered by CStone’s partner Blueprint Medicines.The test kit will detect the D8...
BEIJING and SUZHOU, China, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and com...
News, Short Squeeze, Breakout and More Instantly...
Genetron Holdings Limited Company Name:
GTH Stock Symbol:
NASDAQ Market:
Genetron Holdings Limited Website:
Jet.AI Inc. (JTAI) is expected to report for Q1 2024 Forian Inc. (FORA) is expected to report $-0.02 for Q1 2024 Square Enix Holdings Co. Ltd (SQNXF) is expected to report for Q4 2024 Qutoutiao Inc. (QTT) is expected to report for Q4 2023 Molecular Partners AG (MOLN) is expected t...
BEIJING, March 28, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and c...
BEIJING, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and co...